Consensus report of a joint NCI Thoracic Malignancies Steering Committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "Master Protocols" in lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 10, 2014, Pages 1443-1448

  Malik, Shakun M ^a   Pazdur, Richard ^b   Abrams, Jeffrey S ^a   Socinski, Mark A ^c   Sause, William T ^d   Harpole, David H ^e   Welch, John J ^a   Korn, Edward L ^a   Ullmann, Claudio Dansky ^a   R Hirsch, Fred ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

NCI FDA workshop leading to the inception of "Master Protocols" in lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CISPLATIN; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; TUMOR MARKER;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CONSENSUS; DISEASE FREE SURVIVAL; DNA SEQUENCE; DRUG INDUSTRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOOD AND DRUG ADMINISTRATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PATIENT SELECTION; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY OF LIFE; WORKSHOP; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; LUNG NEOPLASMS; METABOLISM; NATIONAL HEALTH ORGANIZATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNITED STATES;

BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; NATIONAL CANCER INSTITUTE (U.S.); RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84907972945     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000314     Document Type: Article

References (33)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission. Accessed April 2014.
2. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012;18:349-351.
3. Collier R. Rapidly rising clinical trial costs worry researchers. CMAJ 2009;180:277-278.
4. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
5. Laleh A-K, Tito F. Why do phase III clinical trials in oncology fail so often? J Natl Cancer Inst 2012;104:568-569.
6. Hoering A, LeBlanc M, Crowley J. Randomized, phase III clinical trial designs for targeted agents. Clin Cancer Res 2008; 14:4358-4367.
7. Mansfield E, O'Leary TJ, Gutman SI. Food and Drug Administration regulation of in vitro diagnostic devices. J Mol Diagn 2005;7:2-7.
8. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol 2010;28:698-704.
9. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-4034.
10. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers design issues. J Natl Cancer Inst 2010;102:152-160.
11. George SL, Wang X. Targeted clinical trials. In Harrington D (Ed.), Designs for Clinical Trials: Perspectives on Current Issues. Springer, 2012. Pp. 157-177.
12. Freidlin B, Korn EL. Biomarker enrichment strategies: matching trial design to biomarker credentials. Nat Rev Clin Oncol 2014;11:81-90.
13. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
15. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25:2747-2754.
16. Farina G, Longo F, Martelli O, et al. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations. Clin Lung Cancer 2011;12:138-141.
17. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010;16:691-698.
18. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53.
19. Barker AD, Sigman CC, Kelloff GJ et al. I-SPY 2: an adaptive breast cancer trial in the setting of neoadjuvant chemotherapy. Clin Pharm Therap 2009;86:97-100.
20. Korn EL, Freidlin B. Outcome-adaptive randomization: Is it useful? J Clin Oncol 2011;29:771-776.
21. Korn EL, Freidlin B. On the usefulness of outcome-adaptive randomization. J Clin Oncol 2011;29: e393.
22. Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011;29:2439-2442.
23. Polley MY, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst 2013;105:1677-1683.
24. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-1452.
25. Mansfield EA. FDA perspective on companion diagnostics: an evolving paradigm. Clin Cancer Res 2014;20:1453-1457.
26. U.S. Food and Drug Administration. Draft guidance for industry and food and drug administration staff. In vitro companion diagnostic devices. Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf. Accessed July 14, 2011.
27. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
28. Kris M G, Natale R B, Herbst R S et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer JAMA 2003;290:2149-2158.
29. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
30. Johnson BE, Jänne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005;65:7525-7529.
31. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib and erlotinib. Clin Cancer Res 2006;12:3908-3914.
32. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
33. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, randomized, phase 3 study. Lancet Oncol 2011;12:735-742.